132 related articles for article (PubMed ID: 54211)
1. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
Voytek P; Beisler JA; Abbasi MM; Wolpert-DeFilippes MK
Cancer Res; 1977 Jul; 37(7 Pt 1):1956-61. PubMed ID: 67884
[TBL] [Abstract][Full Text] [Related]
4. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
Neil GL; Berger AE; Bhuyan BK; DeSante DC
Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
7. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
Neil GL; Moxley TE; Manak RC
Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
[No Abstract] [Full Text] [Related]
8. Kinetics of the reduction in viability of cultured L1210 leukemia cells exposed to 5-azacytidine (NSC-102816).
Lloyd HH; Dulmadge EA; Wilkoff LJ
Cancer Chemother Rep; 1972 Oct; 56(5):585-91. PubMed ID: 4119906
[No Abstract] [Full Text] [Related]
9. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26.
Chiuten DF; Muggia FM; Johnson RK
Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512
[No Abstract] [Full Text] [Related]
10. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
11. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
Presant CA; Valeriote F; Vietti TJ
Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydrouridine, cytidine analogues, and hemoglobin F.
DeSimone J; Heller P; Molokie RE; Hall L; Zwiers D
Am J Hematol; 1985 Mar; 18(3):283-8. PubMed ID: 2579548
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
Woodman RJ
Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
[No Abstract] [Full Text] [Related]
15. On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.
Wentworth DF; Wolfenden R
Biochemistry; 1975 Nov; 14(23):5099-105. PubMed ID: 53069
[TBL] [Abstract][Full Text] [Related]
16. [Possibilities for the clinical use of 5-azacytidine].
Veselý J; Cihák A
Vopr Onkol; 1977; 23(10):65-73. PubMed ID: 74127
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
Presant CA; Vietti T; Valeriote F
Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of deamination of 14C-cytosine arabinoside (NSC-63878): a useful biologic assay for tetrahydrouridine (NSC-112907).
Furner RL; Mellett LB
Cancer Chemother Rep; 1975; 59(4):717-20. PubMed ID: 809135
[TBL] [Abstract][Full Text] [Related]
19. Dihydro-5-azacytidine hydrochloride, a biologically active and chemically stable analog of 5-azacytidine.
Beisler JA; Abbasi MM; Driscoll JS
Cancer Treat Rep; 1976 Nov; 60(11):1671-4. PubMed ID: 66095
[No Abstract] [Full Text] [Related]
20. Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells.
Momparler RL; Veselý J; Momparler LF; Rivard GE
Cancer Res; 1979 Oct; 39(10):3822-7. PubMed ID: 476619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
